Patents by Inventor P. Elizabeth Rakoczy

P. Elizabeth Rakoczy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS
    Publication number: 20220111015
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Application
    Filed: May 24, 2021
    Publication date: April 14, 2022
    Inventors: Ian J. CONSTABLE, P. Elizabeth RAKOCZY, Chooi-May LAI, Thomas W. CHALBERG, Jr.
  • TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS
    Publication number: 20180311319
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Application
    Filed: April 24, 2018
    Publication date: November 1, 2018
    Inventors: Ian J. CONSTABLE, P. Elizabeth RAKOCZY, Chooi-May LAI, Thomas W. CHALBERG
  • Treatment of ocular neovascularization using anti-VEGF proteins
    Patent number: 10004788
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: June 26, 2018
    Assignee: Avalanche Australia Pty Ltd.
    Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, Jr.
  • TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS
    Publication number: 20180125948
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 10, 2018
    Inventors: Ian J. CONSTABLE, P. Elizabeth RAKOCZY, Chooi-May LAI, Thomas W. CHALBERG, Jr.
  • Treatment of ocular neovascularization using anti-VEGF proteins
    Patent number: 9943573
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: April 17, 2018
    Assignee: Avalanche Australia PTY Ltd.
    Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, Jr.
  • TREATMENT OF AMD USING AAV SFLT-1
    Publication number: 20150004101
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Application
    Filed: May 19, 2014
    Publication date: January 1, 2015
    Applicant: Avalanche Australia Pty Ltd.
    Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, JR.
  • TREATMENT OF AMD USING AAV SFLT-1
    Publication number: 20140371438
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Application
    Filed: May 19, 2014
    Publication date: December 18, 2014
    Applicant: Avalanche Australia Pty Ltd.
    Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, JR.